Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
eFFECTOR Therapeutics, Inc. terminated Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. valued at $9.8 million (effective 2024-05-09).
- Action
- termination
- Agreement
- atm program
- Counterparty
- Cantor Fitzgerald & Co.
- Value
- $9.8 million
- Effective
- 2024-05-09
Exact text from the filing
On May 9, 2024, the Company terminated its Controlled Equity Offering SM Sales Agreement, dated September 1, 2022, with Cantor Fitzgerald & Co. (the “Prior Sales Agreement”), pursuant to which the Company was able sell shares of common stock in “at the market offerings” as defined by Rule 415 of the Securities Act.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
eFFECTOR Therapeutics, Inc. entered into At the Market Offering Agreement with H.C. Wainwright & Co., LLC valued at aggregate offering price of up to $50.0 million (effective 2024-05-09).
- Action
- entry
- Agreement
- atm program
- Counterparty
- H.C. Wainwright & Co., LLC
- Value
- aggregate offering price of up to $50.0 million
- Effective
- 2024-05-09
Exact text from the filing
On May 9, 2024, eFFECTOR Therapeutics, Inc. (the “Company”) entered into an At the Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”), under which the Company may, from time to time, sell shares of the Company’s common stock having an aggregate offering price of up to $50.0 million through the Agent.
View on SEC.gov